[Neurometabolic therapy in secondary prevention of stroke].
OBJECTIVE
To study the efficacy of mexidol in secondary prevention of stroke.


METHODS
We analyzed 3400 patients with stroke which were stratified into 7 groups: patients with cryptogenic ischemic stroke (II), arterial hypertension, atrial fibrillation, metabolic syndrome, syndrome of sleep-induced obstructive apnea/hypnea, diabetes mellitus, vasculitis. The assessment of efficacy was based on the absence of repeated II within 5 years of therapy.


RESULTS
Mexidol reduced the frequency of repeated II both in patients without concomitant diseases and in those with arterial hypertension, syndrome of sleep-induced obstructive apnea/hypnea, vasculitis, diabetes mellitus, atrial fibrillation and metabolic syndrome.


CONCLUSIONS
The reliable efficacy of mexidol in secondary prevention of stroke was found out.
V V
VV
Koval'chuk
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000975:Antioxidants / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010847:Picolines / Q000627:therapeutic use*; D055502:Secondary Prevention / Q000379:methods*; D020521:Stroke / Q000517:prevention & control*; D016896:Treatment Outcome
D000975:Antioxidants; D010847:Picolines; C070020:emoxypine succinate